Key clinical point: Adding molecular imaging to conventional imaging to guide postprostatectomy radiation therapy improves efficacy.
Major finding: The 3-year failure-free survival rate was 63.0% with conventional imaging guidance alone and 75.5% with added fluciclovine PET imaging guidance (P = .033).
Study details: A phase 2/3, randomized trial of 165 men with prostate cancer undergoing postprostatectomy radiation therapy who had detectable prostate-specific antigen but negative conventional imaging results.
Disclosures: The EMPIRE-1 trial was supported by the National Institutes of Health. Dr. Jani disclosed advisory board service for Blue Earth Diagnostics.
Jani A et al. ASTRO 2020, Abstract LBA1.